Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jun;34(2):154-156.
doi: 10.4314/mmj.v34i2.13.

Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male

Murat Sutcu  1 , Doruk Gul  2 , Fatih Atik  3 , Manolya Kara  4
Affiliations
Case Reports

Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male

Murat Sutcu et al. Malawi Med J. 2022 Jun.

Abstract

Pfizer-BioNTech COVID-19 (BNT162b2) conferred a high level of protection against Covid-19 with a proven short-term safety profile. Although cases of vaccine-associated myopericarditis have been reported, the existence of rhabdomyolysis without myocarditis has not yet been published. A 16-year-old, healthy male patient, who did not use any herbal or illegal drugs before, was admitted with muscle pain that developed after the second dose of BNT162b2 vaccine. Cardiac examination and heart enzymes were normal and the patient had significantly higher creatinine kinase levels. The patient, whose enzymes returned to normal with only force hydration therapy, recovered without complications. Reporting the side effects of the vaccine, which has a short history of application to large populations, is of vital importance in the conduct of vaccine development studies and in identifying the risky group in terms of side effects.

Keywords: Pfizer-BioNTech COVID-19; adolescent; rhabdomyolysis.

PubMed Disclaimer

References

    1. Emergency use authorization: Pfizer-BioNTech COVID-19 vaccine. Silver Spring, MD: Food and Drug Administration; 2021. Available from: https://www.fda.gov/emergencypreparedness-and-response/coronavirus-disea....
    1. Food and Drug Administration, author. Pfizer-BioNTech COVID-19 vaccine EUA amendment review memorandum. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. Available from: https://www.fda.gov/media.
    1. Frenck RW, Jr, Klein NP, Kitchin N, et al. C4591001 Clinical Trial Group Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–250. doi: 10.1056/NEJMoa2107456. Available from: - DOI - PMC - PubMed
    1. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–2149. doi: 10.1056/NEJMoa2109730. Available from: - DOI - PMC - PubMed
    1. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–982. doi: 10.15585/mmwr.mm7027e2. Available from: - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources